tirzepatide injection clarksburg / Niacinamide Weight Loss Clinic Rockville, MD

GLP-1 only

Ward et al

placebo at 6 weeks

the analysis included data collected before permanent discontinuation of study intervention and was conducted using the efficacy analysis set

Provider Responsibilities Conduct comprehensive patient assessment before initiating therapy Adjust dosing and monitoring based on individual patient factors Exercise professional clinical judgment in all treatment decisions Consider unique patient circumstances, comorbidities, and risk factors Maintain appropriate documentation of clinical decision-making Scope of Practice Considerations Providers must practice within their scope of training, experience, and applicable state regulations

Specifically, 30.81% of participants receiving semaglutide experienced GI issues, while only 12.7% in the control group did